XILIO THERAPEUTICS, INC. XLO 深 沪
已收盘 11-14 16:00:00 美东时间
0.7072
+0.006
+0.81%
华盛通- 最 高0.7241
- 今 开0.66
- 成交量 45.09万股
- 最 低 0.66
- 昨 收 0.7015
- 总市值 3665.27万
- 52周最高 1.70
- 市盈率 静 --
- 换手率 0.87%
- 52周最低 0.615
- 委 比 98.57%
- 总股本 5182.79万
- 历史最高 27.95
- 量 比 0.37
- 振 幅 9.14%
- 历史最低 0.49
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Xilio Therapeutics Q3 EPS $(0.11) Misses $(0.03) Estimate, Sales $19.066M Beat $18.635M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.03) by 266.67 percent. This is a 50 percent increase over losses of $(0.22) per share from
11-13 20:37
Xilio Therapeutics Presents New Data Across Portfolio, Including Preclinical Data Highlighting Potential For Masked T Cell Engager Platform And Programs, As Well As Phase 1 Data For Efarindodekin Alfa, And Phase 2 Data Related To Ctdna For Vilastobart, At SITC 2025
Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic
11-07 22:14
Xilio Therapeutics Announces It Will Present Late-Breaking Phase 2 Data For Vilastobart At The SITC 40th Annual Meeting Nov 5–9, 2025
Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will present a
10-30 21:05
Xilio Therapeutics Transfers Listing to Nasdaq Capital Market
Xilio Therapeutics ( ($XLO) ) just unveiled an update. On October 2, 2025, Xili...
10-03 19:58
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Xilio Therapeutics将在2025年11月6日至9日举行的SITC年会上展示其肿瘤激活免疫疗法的最新数据，包括vilastobart和XTX301的临床数据，以及T细胞衔接器的临床前研究。主要展示内容包括微卫星稳定的转移性结直肠癌患者的ctDNA作为潜在生物标志物、XTX301的药代动力学数据，以及新型T细胞衔接器的设计概念，均在Gaylord会展中心展出。
10-03 13:00
Xilio Therapeutics Initiates Patient Dosing In Phase 2 Of An Ongoing Phase 1/2 Clinical Trial Evaluating Efarindodekin Alfa As Monotherapy In Patients With Certain Advanced Solid Tumors
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumorsAchievement of milestone extends anticipated cash runway into first quarter of
09-09 19:37
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
Xilio Therapeutics announced the initiation of Phase 2 for efarindodekin alfa (XTX301), a tumor-activated IL-12, in patients with advanced solid tumors, following promising Phase 1 data showing two partial responses and a generally well-tolerated safety profile. The company also achieved a $17.5 million development milestone under its license agreement with Gilead Sciences, extending its cash runway into the first quarter of 2027. Efarindodekin a...
09-09 11:30
Xilio Therapeutics Q2 EPS $(0.16) Misses $(0.08) Estimate, Sales $8.084M Miss $8.210M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.08) by 100 percent. This is a 33.33 percent increase over losses of $(0.24) per share from
08-14 19:33
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
Catalyst Pharmaceuticals, Inc. announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran brings over 25 years of pharmaceutical experience, including strategic leadership roles at Takeda Pharmaceutical Company and as CEO of Timberlyne Therapeutics. Patrick J. McEnany, Chairman of Catalyst's Board, highlighted Dr. Curran's expertise in rare diseases and business development, which will support the company's growth strat...
08-04 12:03
